Coronavirus (COVID-19) Statement

We continue to closely monitor the situation surrounding the COVID-19 pandemic and are following the published recommendations of the CDC and the American Academy of Ophthalmology. We will continue to see our patients and treat any urgent/emergent needs.

With all of our offices open, the following protocols are in place:

1) We have greatly expanded measures to disinfect our office including cleaning between each patient appointment.

2) To limit any potential exposure, we ask you NOT to bring any non-essential person(s) with you to the appointment.

3) If someone must accompany you to your appointment, we ask that they do not enter the office, if at all possible.

4) If you have an upcoming appointment and identify with the following statements, please do not come directly to the office, but instead call us:

• Fever greater than 100.4

• Respiratory symptoms or difficulty breathing

• Exposed to someone with COVID-19 in the past 14 days

• Placed in self/hospital quarantine by medical doctor

 Your health and that of our staff is our guiding priority and we continue to update our protocol to ensure safety for everyone. If you have questions regarding these evolving protocols, please contact our office.

Dr. Dyer CURRICULUM VITAE

David S. Dyer, M.D., F.A.C.S.
 

WORK HISTORY

May 1, 1999 -PRESENT:

  • Retina Associates, LLC 
    Santa Fe Medical Building
    9301 West 74th Street
    Suite 210
    Shawnee Mission, KS 66204
  • Retina Associates, LLC
    6201 College Boulevard
    Suite 200
    Overland Park, KS 66211
  • Retina Associates. LLC
    4100 North Mulberry Drive
    Suite 100
    Kansas City, MO 64116
  • Retina Associates, LLC
    6001 SW 6th Avenue
    Suite 300
    Topeka, KS 66615
  • Retina Associates, LLC
    3700 West 10th Street
    Suite 101
    Sedalia, MO 65301
  • Retina Associates, LLC
    100 NE Missouri Road
    Suite 203
    Lee's Summit, MO 64086

January 1, 1997- April 30, 1999:

  • Mid-America Retina Consultants, P. A.
    4321 Washington Street
    Suite 5000
    Kansas City, MO 64111

July 7, 1994 - March 15, 1997

  • Illinois Retina Associates, S.C.
    71 W. 156th Street
    Suite 400
    Harvey, IL 60426

EDUCATION

  • PREPARATORY: Annandale High School, Annandale, Virginia
  • UNDERGRADUATE: George Mason University, Fairfax Virginia
  • MEDICAL: University of Kansas School of Medicine, Kansas City, Kansas
  • INTERNSHIP: Medicine - University of Kansas Medical Center, Kansas City, Kansas, Department of Internal Medicine (April 1, 1989 - June 30, 1990)
  • RESIDENCY: Ophthalmology - Medical University of South Carolina, Storm Eye Institute, Charleston, South Carolina (July 1, 1990 - June 30, 1993)
  • FELLOWSHIP: Medical Retina - The Wilmer Ophthalmological Institute, The Johns Hopkins University, Baltimore, Maryland (July 7, 1993 - June 30,1994) Fellowship Director: Andrew P. Schachat, M.D.
  • FELLOWSHIP: Surgical Retina - Rush-Presbyterian Hospital/Ingalls Memorial Hospital, Illinois Retina Associates, Harvey, Illinois (July 7, 1994 - June 30, 1995) Fellowship Director: Kirk H. Packo, M.D.

DEGREES EARNED

  • B.S. - January 1984
  • M.D. - May 1989

LICENSURE

  • Diplomat American Board of Ophthalmology
  • Kansas State License
  • Missouri State License
  • Utah State License

MEMBERSHIPS

  • American Academy of Ophthalmology
  • Kansas Medical Society
  • Kansas State Ophthalmological Society
  • Kansas City Society of Ophthalmology and Otolaryngology
  • Kansas City Society of Ophthalmology and Otolaryngology Journal Club
  • Kansas City Medical Society
  • Missouri State Medical Association
  • Kansas Society of Eye Physicians & Surgeons
  • Missouri Society of Eye Physicians & Surgeons
  • F.R.A.M.E.
  • Chicago Medical Society
  • Wilmer Residents Associate
  • ARVO
  • ASRS

ACADEMIC APPOINTMENT

  • Assistant Professor, Rush Medical College, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Illinois (July 7, 1995 - December 31, 1996)

PUBLICATIONS

  • A Kiri, DS Dyer, NM Bressler, SB Bressler, AP Schachat: “Detection of Diabetic Macular Edema: Nidek 3Dx Stereophotography Compared with Fundus Biomicroscopy.” American Journal of Ophthalmology November 1996
  • PJ Gurecki, KR Holden, EE Sahn, DS Dyer, JR Cure: "Developmental Neural Abnormalities and Seizures in Epidermal Nevus Syndrome.” Developmental Medicine and Child Neurology 1996;38:716-723
  • DS Dyer, AM Brant, AP Schachat, SB Bressler, NM Bressler: "Angiographic Features and Outcome of Questionable Recurrent Choroidal Neovascularization."   American Journal of Ophthalmology 1995;120:497-505
  • DS Dyer: “Scleral Patch Graft for Closure of Sclerotomies.” Vitreoretinal Surgery and Technology 1995;7(3):1-4
  • DS Dyer, NM Bressler: “Laser Wavelength-It’s Role in the Treatment of Vitreoretinal Diseases.” Current Opinion in Ophthalmology 1994;5:III:35-43
  • DS Dyer, KW Small, ME Wilson, GS Pai: “Alstrom Syndrome: "A Case Misdiagnosed as Bardet-Biedl Syndrome.” Journal of Pediatric Ophthalmology and Strabismus 1994;31:272-274

PRESENTATIONS

  • DS Dyer: “Look Deep Into My Eyes.” Greater Kansas City ASORN, Kansas City, Missouri (March 27, 2010)
  • DS Dyer: “Integrated Pressure Infusion and IOP Control.” Constellation Vision System (November 6, 2008)
  • DS Dyer, GM Fox, BA Cooper: “Outcomes and Complications of 25-gauge Vitrectomies.” Masters of the ASRS, Nassau, Bahamas (March 13-16, 2005)
  • DS Dyer: “Babes in Arms - Retinopathy of Prematurity.” Greater Kansas City ASORN, Kansas City, Missouri (February 28, 2004)
  • DS Dyer: “Diabetic Retinopathy and Cataract Surgery.” The Art of Diabetic Care Conference, Kansas City, Missouri (September 20, 1997)
  • A Kiri, SR O’Connell, DS Dyer, NM Bressler, SB Bressler, AP Schachat, D Finkelstein: “Comparison of Stereo Photography by Nidek 3Dx Camera with Zeiss Camera in Detecting Diabetic Macular Edema.” ARVO Annual Meeting, Fort Lauderdale, Florida (May 11-16, 1997)
  • DS Dyer, A Kiri, SR O’Connell, NM Bressler, SB Bressler, AP Schachat: “Intra- and Inter-Observer Agreement in Detecting Diabetic Macular Edema by Grading Nidex 3DX Stereo Photographs.” ARVO Annual Meeting, Fort Lauderdale, Florida (May 11-16, 1997)
  • SR O’Connell, A Kiri, DS Dyer, CJ Hiner, NM Bressler, SB Bressler, AP Schachat: “The Influence of Training Ophthalmologist to Grade Fundus Stereo Photographs for Detecting Diabetic Macular Edema.” ARVO Annual Meeting, Fort Lauderdale, Florida (May 11-16, 1997)
  • DS Dyer: “Diabetes I - Medical Consideration, ETDRS, DCCT and Eurodiab IDDM Trial Results, Nonproliferative Diabetic Retinopathy.” The 6th Annual Rush Medical College Ophthalmology Clinical Review Course, Chicago, Illinois (April 13, 1997)
  • DS Dyer: “Current Concepts and Indications for Vitreo-Retinal Surgery.” Copley-Mercy Consortium, Aurora, Illinois (November 5, 1996)
  • DH Orth, DS Dyer: “Foveal Sparing Photocoagulation for Exudative Age Related Macular Degeneration.” The First Jerusalem International Congress On Retinal and Vitreous Diseases, Jerusalem, Israel (June 30 - July 4, 1996)
  • DS Dyer: “Disorders of the Posterior Pole.” Diagnostic Pharmaceutical Agent Training and Certification Course, The National Eye Research Foundation, Oak Lawn, Illinois (March 23-24, 1996)
  • DS Dyer: “Subretinal Surgery: Advances in Indications and Techniques.” The 5th Annual Rush Medical College Ophthalmology Clinical Review Course, Chicago, Illinois (March 24, 1996)
  • DS Dyer: “Anatomy and Pathophysiology of Age-Related Macular Degeneration.” The 5th Annual Rush Medical College Ophthalmology Clinical Review Course, Chicago, Illinois (March 22, 1996)
  • DS Dyer: “Diabetic Retinopathy.” The Lions of Illinois Foundation Executive Meeting, Peoria, Illinois (February 16, 1996)
  • DS Dyer: “Techniques of Silicone Oil Removal.” Silicone Oil Surgery: A Multi-Centered Course, Chicago, Illinois (October 14, 1995)
  • DS Dyer, KH Packo, R Shetty: “YAG Posterior Hyaloidotomy for Subhyaloid Hemorrhage.” The Retina Society, Twenty-Sixth Scientific Session, London, England (September 6-10, 1995)
  • DS Dyer, LM Jampol, KH Packo: “Evaluation of Computerized Overlay Techniques in Digital Angiography.” ARVO Annual Meeting, Fort Lauderdale, Florida (May 14-19, 1995)
  • A Kiri, DS Dyer, NM Bressler, SB Bressler, AP Schachat: “Comparison of Nidek 3Dx Camera with Fundus Biomicroscopy in the Detection of Diabetic Edema.” ARVO Annual Meeting, Fort Lauderdale, Florida (May 14-19, 1995)
  • A Kiri, DS Dyer, NM Bressler, SB Bressler, AP Schachat: “Comparison of Nidek 3Dx Camera with Fundus Biomicroscopy in the Detection of Diabetic Edema.” The 54th Clinical Meeting of the Wilmer Residents Association (April 27-29, 1995)
  • DS Dyer: “Diabetic Retinopathy: Review of Diabetes Mellitus, DCCT Trial and the ETDRS Trial.” The 4th Annual Rush Medical College Ophthalmology Clinical Review Course, Chicago, Illinois (March 12, 1995)
  • DS Dyer, AM Brant, AP Schachat, SB Bressler, NM Bressler: “Patterns of Questionable Recurrent Choroidal Neovascularization.” ARVO Annual Meeting, Sarasota, Florida (May 1-5, 1994)
  • AM Brant, DS Dyer, AP Schachat, Bressler SB, Bressler NM: “Subtle Clinical Signs of Recurrent Choroidal Neovascularization.” ARVO Annual Meeting, Sarasota, Florida (May 1-5, 1994)
  • DS Dyer, AM Brant, AP Schachat, SB Bressler, NM Bressler: “Patterns of Questionable Recurrent Choroidal Neovascularization.” 53rd Clinical Meeting of the Wilmer Residents Association (April 21-23, 1994)
  • AM Brant, DS Dyer, AP Schachat, SB Bressler, NM Bressler: “Subtle Clinical Signs of Recurrent Choroidal Neovascularization.” 53rd Clinical Meeting of the Wilmer Residents Association (April 21-23, 1994)
  • DS Dyer, YY Palesch, LP King: “Ocular Hypertension Following Pars Plana Vitrectomy.” Poster at the 1993 American Academy of Ophthalmology Annual Meeting, Chicago, Illinois (November 14-18, 1993)
  • DS Dyer, LP King: “Ocular Hypertension Following Pars Plana Vitrectomy.” Pediatric and Strabismus Update, Kiawah Island, South Carolina (June 1-3, 1993)
  • DS Dyer, LP King: “Risk Factors and Treatment of Postoperative Intraocular Pressure Spike Following Vitrectomy.” ARVO Annual Meeting, Sarasota, Florida (May 2-7, 1993)
  • DS Dyer: “Infection Control in the Office.” 1992 Corneal and External Disease Update, Charleston, South Carolina (May 22-24, 1992)
  • DS Dyer: “Post-op Pressure Rise in Intravitreal Gas Injection.” 1992 Corneal and External Disease Update, Charleston, South Carolina (May 22-24, 1992)
  • DS Dyer, KW Small, ME Wilson, GS Pai: “Alstrom Syndrome: A Case Misdiagnosed as Bardet-Biedl Syndrome.” The 14th Annual Ophthalmic Genetics Study Club, Anaheim, California (October 12, 1991)
  • DS Dyer: “Indications and Usage of Low Dose Fluorescein Angiograms.” Glaucoma Diagnostic and Therapeutic Update, Kiawah Island, South Carolina (April 12-14, 1991)

ARTICLES IN PREPARATION

  • AM Brant, DS Dyer, AP Schachat, SB Bressler, NM Bressler: “Subtle Signs of Questionable Recurrent Choroidal Neovascularization.” (Submitted to Retina)
  • DS Dyer, KH Packo: “Retinotomies and Retinectomies.” (To be published in Ophthalmic Practice)

CLINICAL RESEARCH

  • Alcon: C-01-99, Sub-Investigator, Posterior Juxtascleral Injection of Anecortave Acetate versus Sham for Inhibition of CNV in Non-Exudative AMD, 08/2003 – 08/2005.
  • Alcon: C-05-62, Principal Investigator, Clinical Evaluation of the Safety and Efficacy of Preservative-Free Triamcinolone Acetonide Sterile Suspension for Visualization During Vitreoretinal Surgery, 08/2007 - 09/2007.
  • Alcon: C-02-60, Sub-Investigator, Anecortave Acetate Risk Reduction Trial for Patients with Non-Neovascular AMD, 03/2004-08/2008.
  • Alcon: C-04-59, Sub-Investigator, Interval Dose Evaluation of Anecortave Acetate for those with Neovascular AMD, 01/2005 – 02/2008.
  • Alcon: C-12-006, Sub-Investigator, Eylea vs. ESBA1008 for the Treatment of Exudative Age-Related Macular Degeneration, 03/2013 - 04/2013.
  • Alcon: RTH258-C001, Sub-Investigator, Intravitreal RTH258 vs. Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration, 03/2015 - present.
  • Allergan: 206207-008, Sub-Investigator, Posurdex Retinal Vein Occlusion, 01/2005 – 02/2009.
  • Allergan: 206207-010, Sub-Investigator, Posurdex Diabetic Macular Edema, 03/2005 – 03/2013.
  • Allergan: 208397-001, Sub-Investigator, AGN-208397 Retinal Vein Occlusion, 11/2010 -04/2013.
  • DRCR: Intravitreal Triamcinolone study B, Principal Investigator, Focal Laser Treatment versus Intravitreal Injection Triamcinolone for Treatment of Diabetic Macular Edema, 06/2005 – 10/2006.
  • DRCR: Protocol T, Sub-Investigator, Aflibercept, Bevacizumab, and Ranibizumab for the Treatment of Diabetic Macular Edema, 12/2012 - 08/2015
  • DRCR: Protocol V, Sub-Investigator, Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity, 11/2013 - present.
  • DRCR: Protocol W, Sub-Investigator, Intravitreal Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk, 02/2016 - present.
  • DRCR: Protocol AA, Sub-Investigator, Peripheral Diabetic Retinopathy Lesions on Ultrawide-Field Images and Risk of Diabetic Retinopathy Worsening Over Time, 07/2014 - present.
  • Eyetech/OSI: EOP1023, Principal Investigator, Intravitreal Injection of Pegaptanib Sodium for Neovascular AMD, 05/2006 – 07/2008.
  • Eyetech IST: Principal Investigator, Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease (PRESERVE), Sub-Investigator, Intravitreal Injections of Pegaptanib Every 4 weeks Compared to every 6 weeks for the Treatment of Diabetic Macular Edema, 05/2009 - 10/2011.
  • Eyetech: EOP1024, Investigator, Intravitreal Injection of Pegaptanib Sodium administered every 6 weeks for 48 weeks for Subfoveal Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, or Retinal Vein Occlusion to Determine the Adverse Effects on the Corneal Endothelium, 04/2010 – 10/2013.
  • Genaera: 301, Principle Investigator, Squalamine Lactate IV Infusion for Treatment of Neovascular AMD, 09/2005 – 09/2008.
  • Genentech: FVF4165g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Branch Retinal Vein Occlusion, 02/2008 – 01/2010.
  • Genentech: FVF4166g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion, 02/2008 – 01/2010.
  • Genentech: FVF4168g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Diabetic Macular Edema, 08/2007 – 12/2012.
  • Genentech: FVF4295, Sub-Investigator, Evaluation of Ranibizumab on Ease of Procedure and Complications in PDR Requiring Vitrectomy, 09/2007 – 10/2010.
  • Genentech: FVF3426g, Sub-Investigator, Intravitreal Injections of Ranibizumab for Branch Retinal Vein Occlusion and Central Retinal Vein Occlusion for Subjects who have Completed a Genentech Sponsored Ranibizumab Study, 02/2009 – 10/2010.
  • Genentech: FVF4579g, Sub-Investigator, Intravitreal Injection of Either 0.5mg or 2.0mg Ranibizumab Administered Monthly or on an as Needed Basis for Subjects with Subfoveal Neovascular Age-Related Macular Degeneration, 06/2009 – 09/2012.
  • Genentech: FVF4967g, Sub-Investigator, Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion, 03/2011 - 01/2013.
  • Genentech:  GX29176, Sub-Investigator, Study to Assess the efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. 11/2014 - present.
  • Genentech: GX30191, Sub-Investigator, Open Label Extension to Evaluate the Long-term Safety and Tolerability of Lampalizumab in Patients with Geographic Atrophy Secondary to NNVAMD who have Completed a Roche-Sponsored Study, 10/2016 - present.
  • Genentech:  GR40548, Sub-Investigator, Phase III, Active-Comparator Study of the Efficacy, Safety and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration, 11/2019 - present.
  • Genentech:  GR40349, Sub-Investigator, Phase III, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema., 11/2018 - present.
  • Genentech: GR40306, Sub-Investigator, Phase III, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Neovascular Age-Related Macular Degeneration, 03/2019 - present.
  • Genentech: GR40549, Sub-Investigator, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Deliver System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration, 10/2020 - present.
  • Genentech: GR40550, Sub-Investigator, Phase III, Study of the Efficacy, Safety and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema, 09/2019 - present.
  • Genentech: GR41675, Sub-Investigator, Phase III, Study of the Efficacy, Safety and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Retinopathy,  09/2020 - present.
  • Eli Lily: B7A-MC-MBCM, Sub-Investigator, Ruboxistaurin Mesylate for Patients with Diabetic Retinopathy. 01/2003– 04/2006.
  • Eli Lily: B7A-MC-MBDV, Sub-Investigator, Open-Label treatment for Patients Completing Study B7A-MC-MBCM, 02/2006-11/2008.
  • Kodiak: KSI-CL-102, Sub-Investigator, Phase III, Active Comparator-Controlled Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular Age-Related Macular Degeneration. 09/2019 - present.
  • MyLan: MYL-1701P-3001, Sub- Investigator, Active-Controlled, Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Aflibercept in Subjects with Diabetic Macular Edema, 08/2018 - present.
  • National Eye Institute SCORE2: Sub-Investigator, Study of Comparative Treatments for Retinal Vein Occlusion, 10/2014 - 5/2016.
  • NGM Bio: NGM621-GA-201, Sub-Investigator, Phase II, Double-Masked, Sham-Controlled Study of the Efficacy and Safety of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration, 09/2020 - present.
  • Novartis: Principal Investigator, Insight CNV Registry, 11/2005 – 08/2006.
  • Novartis: CRTH258B2301, Sub-Investigator, Phase III Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment Due to Diabetic Macular Edema, 09/2018 - present.
  • Novartis: CRTH258AUS04, Sub-Investigator, Phase III Study to Assess Safety and Efficacy of Brolucizumab 6mg q4weeks Compared to Aflibercept 2mg q4weeks in Patients with Neovascular Age-Related Macular Degeneration with Persistent Retinal Fluid, 12/2018 - present.
  • Novartis: CRTH258C2301, Sub-Investigator, Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion, 07/2019 - present. 
  • Novartis: CRTH258C2302, Sub-Investigator, Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion, 07/2018 - present.
  • Novartis: CRTH258B2305, Sub-Investigator, Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment Due to Diabetic Macular Edema, 10/2019 - present.
  • Ophthotech: OPH3000, Principal Investigator, Intravitreal Injection of Volociximab in Combination with Ranibizumab for Neovascular Age-Related Macular Degeneration, 10/2008 – 12/2009.
  • Ophthotech: OPH1001, Principal Investigator, Intravitreal Injection of E10030 (Anti-PDGF-B Pegylated Aptamer) in Combination with Ranibizumab for Neovascular Age-Related Macular Degeneration, 05/2010 – 11/2001.
  • Ophthotech:  OPH1003, Principal Investigator, Intravitreal Injection of Fovista (Anti-PDGF-B Pegylated Aptamer) in Combination with Lucentis vs. Lucentis Monotherapy for the Treatment of Neovascular Age-Related Macular Degeneration, 09/2013 - 01/2017.
  • Ophthotech: OPH1004, Principal Investigator, Intravitreal Injection of Fovista (Anti-PDGF Pegylated Aptamer) in Combination with Eylea or Avastin Compared vs. Eylea or Avastin Monotherapy for the Treatment of Neovascular Age-Related Macular Degeneration, 07/2015 - 09/2017.
  • Pan Optica:  PAN-01-101, Principal Investigator, Study to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration, 01/2014 - 03/2016.
  • Regeneron: R2176-3-AMD-1417, Sub-Investigator, multiple Dose, Regimen Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration, 06/2015 - 04-2017.
  • Regeneron: R910-3-DME-1518, Sub-Investigator, Intravitreal REGN910-3 for Patients with Diabetic Macular Edema, 05/2016 - 10/2017.
  • Principal Investigator, Submacular Surgery Trials. 1998 - 1999
  • Principal Investigator, An Open Label Study of the Safety and Efficacy of Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients with Cytomegalovirus Retinitis. (Protocol ISIS 2922-CS7) 1997
  • Clinical Investigator, ASPEN Diabetic Retinopathy Substudy. 1997
  • Clinical Investigator, Age-Related Eye Disease Study (AREDS). (NIH Grant #NO1-#EY02124) 1995
  • Co-Investigator, Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity. 1995
  • Clinical Investigator, Silicone Oil Study. 1995
  • Clinical Investigator, Perfluorone Study. 1995

A Vision to be the Best

As the largest group of Retina specialists in the Greater Kansas City, Topeka, Sedalia and surrounding areas we offer multiple professional offices to serve you.  Each of our offices are staffed and equipped to provide the highest level of health care service and access in a comfortable environment.

Dr. Dyer is currently seeing patients at our Shawnee Mission, Kansas City, and Ottawa locations.

Retina Associates, PA logo

Retina Associates, LLC

Retina Associates, LLC is an advanced medical practice devoted to the diagnosis and treatment of retinal, macular, and vitreous diseases. Together, our eye care physicians belong to various prestigious organizations: 

  • American Board of Ophthalmology
  • American Academy of Ophthalmology
  • Association for Research in Vision and Ophthalmology
  • American College of Surgeons
  • American Society of Retina Specialists

Our mission is to help every patient preserve or restore their sight through our advanced treatment options. To discuss your needs with one of our doctors, request an appointment online or call us at (913) 831-7400.

Contact Us

Rate, Review & Explore

Social Accounts Sprite
Google map image of our location in Shawnee Mission, KS

Shawnee Mission Office

9301 W 74th St
Ste 210
Shawnee Mission, KS 66204

Open Today 8:00am - 5:00pm

What is the best time for you?

Add additional time

Tell us a bit about yourself...

(913) 831-7400 Send a message